125 related articles for article (PubMed ID: 11397625)
21. Long-term study of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.
Polwichai P; Trakulsomboon S; Dejsirilert S; Thongmali O; Sawanpanyalert P; Aswapokee N; Buppanharun W
J Med Assoc Thai; 2009 Aug; 92 Suppl 4():S53-8. PubMed ID: 21294502
[TBL] [Abstract][Full Text] [Related]
22. Comparison of in vitro antimicrobial activity of cefamandole and cefazolin with cephalothin against over 8,000 clinical bacterial isolates.
Jones RN; Fuchs PC
Antimicrob Agents Chemother; 1976 Jun; 9(6):1066-9. PubMed ID: 938021
[TBL] [Abstract][Full Text] [Related]
23. Beta-lactamase resistance of cephazolin and other cephalosporins.
Goodwin CS; Hill JP
Scott Med J; 1976 Sep; 20(5):236-9. PubMed ID: 772808
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
[TBL] [Abstract][Full Text] [Related]
25. Variable in vitro activity of cefaclor, cephalothin and cefadroxil against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
Larsson P; Lincoln K; Lind L; Sandberg T
Scand J Infect Dis; 1988; 20(4):421-4. PubMed ID: 3057617
[TBL] [Abstract][Full Text] [Related]
26. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.
Hawser SP; Badal RE; Bouchillon SK; Hoban DJ; Hsueh PR
Int J Antimicrob Agents; 2010 Sep; 36(3):293-4. PubMed ID: 20598511
[No Abstract] [Full Text] [Related]
27. Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections.
Jain JG; Housman ST; Nicolau DP
J Antimicrob Chemother; 2014 Sep; 69(9):2443-7. PubMed ID: 24827890
[TBL] [Abstract][Full Text] [Related]
28. Tigecycline susceptibility in Klebsiella pneumoniae and Escherichia coli causing neonatal septicaemia (2007-10) and role of an efflux pump in tigecycline non-susceptibility.
Roy S; Datta S; Viswanathan R; Singh AK; Basu S
J Antimicrob Chemother; 2013 May; 68(5):1036-42. PubMed ID: 23335112
[TBL] [Abstract][Full Text] [Related]
29. [In vitro susceptibility of Escherichia coli and Klebsiella sp. to antibiotics].
Igari J; Shitara M; Shitara M; Yoshimoto K; Hayashi Y
Jpn J Antibiot; 1990 Apr; 43(4):659-69. PubMed ID: 2199690
[TBL] [Abstract][Full Text] [Related]
30. Impact of revised susceptibility breakpoints on bacteremia of Klebsiella pneumoniae: Minimum inhibitory concentration of cefazolin and clinical outcomes.
Chuang CH; Liu MF; Lin CF; Shi ZY
J Microbiol Immunol Infect; 2016 Oct; 49(5):679-684. PubMed ID: 25442869
[TBL] [Abstract][Full Text] [Related]
31. Limited diversity in the gene pool allows prediction of third-generation cephalosporin and aminoglycoside resistance in Escherichia coli and Klebsiella pneumoniae.
Ginn AN; Zong Z; Wiklendt AM; Thomas LC; Merlino J; Gottlieb T; van Hal S; Harkness J; Macleod C; Bell SM; Leroi MJ; Partridge SR; Iredell JR
Int J Antimicrob Agents; 2013 Jul; 42(1):19-26. PubMed ID: 23706544
[TBL] [Abstract][Full Text] [Related]
32. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.
Shahid M; Malik A; Akram M; Agrawal LM; Khan AU; Agrawal M
Int J Infect Dis; 2008 May; 12(3):256-64. PubMed ID: 17981482
[TBL] [Abstract][Full Text] [Related]
33. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
34. CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia.
Martinez P; Garzón D; Mattar S
Braz J Infect Dis; 2012; 16(5):420-5. PubMed ID: 22964287
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activity of cephalosporins.
Stewart D; Bodey GP
J Antibiot (Tokyo); 1976 Feb; 29(2):181-6. PubMed ID: 6411
[TBL] [Abstract][Full Text] [Related]
36. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan.
Chang YY; Chuang YC; Siu LK; Wu TL; Lin JC; Lu PL; Wang JT; Wang LS; Lin YT; Huang LJ; Fung CP
J Microbiol Immunol Infect; 2015 Apr; 48(2):219-25. PubMed ID: 25074627
[TBL] [Abstract][Full Text] [Related]
37. Activity of cefepime, cefotaxime, ceftazidime, and aztreonam against extended-spectrum-producing isolates of Klebsiella pneumoniae and Escherichia coli from Chilean hospitals.
Zemelman C; Bello H; Domínguez M; González G; Mella S; Zemelman R
Diagn Microbiol Infect Dis; 2001; 40(1-2):41-3. PubMed ID: 11448562
[TBL] [Abstract][Full Text] [Related]
38. [In vitro activity of cefoxitin, a new cephalosporin (author's transl)].
Shah PM; Zwischenbrugger H; Stille W
MMW Munch Med Wochenschr; 1976 Nov; 118(45):1469-72. PubMed ID: 825763
[TBL] [Abstract][Full Text] [Related]
39. [Microbiological evaluation of cefoxitin, a new beta-lactamase resistant cephamycin antibiotic, compared to cephalothin, cephaloridine and cefazolin].
Schassan HH; Bentfeld G
Fortschr Med; 1978 Aug; 96(30):1510-7. PubMed ID: 669547
[TBL] [Abstract][Full Text] [Related]
40. Dissemination of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli in Thai hospitals.
Niumsup PR; Tansawai U; Boonkerd N; Polwichai P; Dejsirilert S
J Infect Chemother; 2008 Dec; 14(6):404-8. PubMed ID: 19089552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
